Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.41 |
| ▸ | PAK4 | O96013 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 4/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | PLK4 | O00444 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929547 | 0.90 | PAK1 (0.37) | RETPAK1PAK4JAK2NTRK1 | |
| SCHEMBL3926826 | 0.88 | RET (0.40) | RETPAK1PAK4JAK2NTRK1 | |
| SCHEMBL3924185 | 0.83 | JAK2 (0.37) | RETPAK1PAK4JAK2NTRK1 | |
| SCHEMBL4213948 | 0.83 | JAK2 (0.37) | RETPAK1PAK4JAK2NTRK1 | |
| SCHEMBL3928070 | 0.81 | ROCK2 (0.37) | PAK1PAK4ROCK2 | |
| SCHEMBL3923661 | 0.81 | NAPEPLD (0.35) | ROCK2 | |
| SCHEMBL3931669 | 0.81 | NAPEPLD (0.39) | ROCK2BTK | |
| SCHEMBL15484970 | 0.81 | NPC1 (0.39) | PAK4ROCK2 | |
| SCHEMBL1722352 | 0.80 | JAK2 (0.58) | PAK1PAK4JAK2NTRK1ROCK2 | |
| SCHEMBL3935055 | 0.79 | CHIT1 (0.39) | PAK1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | RET 114/4885PAK1 529/4885PAK4 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.